Literature DB >> 10506604

Effect of radiotherapy and chemotherapy on pulmonary function after treatment for breast cancer and lymphoma: A follow-up study.

J C Theuws1, S H Muller, Y Seppenwoolde, S L Kwa, L J Boersma, G A Hart, P Baas, J V Lebesque.   

Abstract

PURPOSE: To determine the changes in pulmonary function tests (PFTs) 0 to 48 months after treatment for breast cancer and lymphoma. PATIENTS AND METHODS: The alveolar volume (V(A)), vital capacity, forced expiratory volume in 1 second, and corrected transfer factor of carbon monoxide (T(L,COc)) were measured in 69 breast cancer and 41 lymphoma patients before treatment and 3, 18, and 48 months after treatment with radiotherapy alone or radiotherapy in combination with chemotherapy (mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine; cyclophosphamide, epidoxorubicin, fluorouracil; cyclophosphamide, thiotepa, carboplatin; cyclophosphamide, methotrexate, fluorouracil). The three-dimensional dose distribution in the lung of each patient was converted to the mean lung dose. Statistical analysis was used to evaluate the changes in PFT values over time in relation to age, sex, smoking, chemotherapy, and the mean lung dose.
RESULTS: After an initial reduction in PFT values at 3 months, significant recovery was seen at 18 months for all patients. Thereafter, no further improvement could be demonstrated. Reductions in spirometry values and V(A) were related to the mean lung dose only (0.9% per Gy at 3 months and 0.4% per Gy mean dose at 18 months). T(L,COc) decreased 1. 1% per Gy mean dose and additionally decreased 6% when chemotherapy was given after radiotherapy. Chemotherapy administered before radiotherapy reduced baseline T(L,COc) values by 8% to 21%. All patients showed an improvement of 5% at 18 months.
CONCLUSION: On the basis of the mean lung dose and the chemotherapy regimen, the changes in PFT values can be estimated before treatment within 10% of the values actually observed in 72% to 85% of our patients with healthy lungs.

Entities:  

Mesh:

Year:  1999        PMID: 10506604     DOI: 10.1200/JCO.1999.17.10.3091

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  9 in total

1.  The impact of induction chemotherapy and the associated tumor response on subsequent radiation-related changes in lung function and tumor response.

Authors:  Jingfang Mao; Zafer Kocak; Sumin Zhou; Jennifer Garst; Elizabeth S Evans; Junan Zhang; Nicole A Larrier; Donna R Hollis; Rodney J Folz; Lawrence B Marks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-02-02       Impact factor: 7.038

2.  Changes in pulmonary function after three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, or proton beam therapy for non-small-cell lung cancer.

Authors:  Jose L Lopez Guerra; Daniel R Gomez; Yan Zhuang; Lawrence B Levy; George Eapen; Hongmei Liu; Radhe Mohan; Ritsuko Komaki; James D Cox; Zhongxing Liao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-13       Impact factor: 7.038

3.  Decreased Lung Perfusion After Breast/Chest Wall Irradiation: Quantitative Results From a Prospective Clinical Trial.

Authors:  Adam L Liss; Robin B Marsh; Nirav S Kapadia; Daniel L McShan; Virginia E Rogers; James M Balter; Jean M Moran; Kristy K Brock; Matt J Schipper; Reshma Jagsi; Kent A Griffith; Kevin R Flaherty; Kirk A Frey; Lori J Pierce
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-10-19       Impact factor: 7.038

Review 4.  Treatment for radiation-induced pulmonary late effects: spoiled for choice or looking in the wrong direction?

Authors:  Jacqueline P Williams; Carl J Johnston; Jacob N Finkelstein
Journal:  Curr Drug Targets       Date:  2010-11       Impact factor: 3.465

5.  Breast cancer survivors with preserved or rescued cardiorespiratory fitness have similar cardiac, pulmonary and muscle function compared to controls.

Authors:  Georgios Grigoriadis; Sara R Sherman; Natalia S Lima; Elizabeth C Lefferts; Brooks A Hibner; Hannah C Ozemek; Oana C Danciu; Dimitra Kanaloupitis; Bo Fernhall; Tracy Baynard
Journal:  Eur J Appl Physiol       Date:  2022-07-07       Impact factor: 3.346

6.  Lung function changes after chemoradiation therapy in patients with lung cancer treated by three usual platinum combinations.

Authors:  Vasilios Mihailidis; Stavros Anevlavis; Georgia Karpathiou; George Kouliatsis; Argyrios Tzouvelekis; Paul Zarogoulidis; Paschalis Ntolios; Paschalis Steiropoulos; Demosthenes Bouros; Marios E Froudarakis
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 7.  Cancer survivors in the United States: a review of the literature and a call to action.

Authors:  Manuel Valdivieso; Ann M Kujawa; Tisha Jones; Laurence H Baker
Journal:  Int J Med Sci       Date:  2012-01-17       Impact factor: 3.738

8.  Health profiles of 996 melanoma survivors: the M. D. Anderson experience.

Authors:  Charles Stava; Martha Beck; L Todd Weiss; Adriana Lopez; Rena Vassilopoulou-Sellin
Journal:  BMC Cancer       Date:  2006-04-18       Impact factor: 4.430

9.  Changes in lung volume parameters regarding the received dose in the lobes of the lungs after locoregional radiotherapy of breast cancer.

Authors:  Mahsa Abdemanafi; Mohammad Bagher Tavakoli; Ali Akhavan; Iraj Abedi
Journal:  Rep Pract Oncol Radiother       Date:  2019-10-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.